This example of personalized medicine involves exploiting the highly selective proteins that are expressed by patients’ B-cells. Bullet Biotechnology isolates the specific idiotypic (Id) protein from patients with B-cell lymphomas (CLL – chronic lymphocytic leukemia, and NHL – non-Hodgkin’s lymphoma) and expresses it on the surface of a virus-like particle to provoke a highly specific anti-Id response against B-cell clones expressing the specific Id protein. Continue reading →